An Open-label, Randomized Crossover Study to Evaluate the Effect of ipragliflozin on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glimepiride in Healthy Subjects and Vice Versa
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2014
At a glance
- Drugs Ipragliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 01 Oct 2012 Part 1 results published in the Diabetes, Obesity and Metabolism.
- 18 Apr 2012 Results published in the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 02 Mar 2011 New trial record